Moreover, we find that the knockdown ofIL-1β also enhances the efficacy of lenvatinib, and recombinant IL-1β protein rescues cell viability, which is reduced by lenvatinib in HCC cells. Here, IL1B is linked to hepatocellular carcinoma.